Fineotex Chemical Q2 revenue rises 169%, PAT gains 71%

Fineotex Chemical Limited reported consolidated total income from operations of Rs 391.41 crore for Q2 FY 2026-27, up 169.14% from Rs 145.43 crore a year earlier, while profit after tax rose 70.82% to Rs 44.55 crore. The board approved the unaudited quarterly and half-year results on November 13, 2026.

How did Fineotex Chemical perform in Q2 FY 2026-27?

Fineotex Chemical’s consolidated total income from operations increased by Rs 245.98 crore year on year in Q2 FY 2026-27, reaching Rs 391.41 crore from Rs 145.43 crore in the corresponding quarter of the previous financial year. The reported increase of 169.14% means total income from operations was about 2.69 times the prior-year quarterly level.

Operating earnings before interest, tax, depreciation and amortisation, or EBITDA, rose 92.04% to Rs 59.59 crore in Q2 FY 2026-27 from Rs 31.03 crore a year earlier. Consolidated profit after tax, or PAT, increased by Rs 18.47 crore to Rs 44.55 crore from Rs 26.08 crore, a rise of 70.82%.

Why did Q2 income grow faster than earnings?

Fineotex Chemical reported that Q2 FY 2026-27 total income from operations grew 169.14%, faster than operating EBITDA growth of 92.04% and PAT growth of 70.82%. In absolute terms, income increased by Rs 245.98 crore, compared with increases of Rs 28.56 crore in operating EBITDA and Rs 18.47 crore in PAT.

The November 13, 2026 announcement does not provide a cost breakdown, product mix, subsidiary contribution or other explanation for the different growth rates. It identifies the figures as consolidated results, so they cover the group rather than only Fineotex Chemical’s standalone operations.

Based on the reported figures, operating EBITDA was equivalent to about 15.22% of Q2 total income from operations, compared with about 21.34% in the corresponding previous-year quarter. PAT was about 11.38% of Q2 income, against about 17.93% a year earlier; these are calculations from the announced figures, not margins separately stated by Fineotex Chemical.

How did Fineotex Chemical perform in H1 FY 2026-27?

Fineotex Chemical reported consolidated total income from operations of Rs 778.13 crore for H1 FY 2026-27, up 166.81% from Rs 291.64 crore in the corresponding period of the previous financial year. The six-month increase was Rs 486.49 crore, reflecting the two quarters ended September 30, 2026.

Operating EBITDA for H1 FY 2026-27 rose 111.22% to Rs 118.74 crore from Rs 56.22 crore in the year-earlier half. PAT increased 81.51% to Rs 92.75 crore from Rs 51.10 crore, producing an absolute increase of Rs 41.65 crore.

What does the half-year comparison show?

Fineotex Chemical’s H1 FY 2026-27 income growth of 166.81% was higher than its EBITDA growth of 111.22% and PAT growth of 81.51%, matching the pattern reported for Q2. H1 operating EBITDA increased by Rs 62.52 crore, while total income from operations increased by Rs 486.49 crore over the corresponding previous-year period.

Calculated operating EBITDA as a share of H1 income was about 15.26% in H1 FY 2026-27, compared with about 19.28% in the year-earlier half. Calculated PAT as a share of income was about 11.92%, compared with about 17.52%; Fineotex Chemical did not give a line-item explanation for these changes in its highlights.

The Rs 92.75 crore H1 PAT was higher than the Rs 44.55 crore Q2 PAT because H1 covers the six months ended September 30, 2026. The company’s release does not supply separate Q1 FY 2026-27 figures, so the supplied announcement does not permit a direct quarter-on-quarter comparison.

What operational measures did Fineotex Chemical disclose?

Fineotex Chemical said consolidated business volumes increased by approximately 132.30% in H1 FY 2026-27 compared with the corresponding period of the previous financial year. That volume increase was disclosed alongside H1 total income from operations of Rs 778.13 crore, which rose 166.81% year on year.

Fineotex Chemical also reported consolidated return on invested capital, or ROIC, of approximately 36.12% for H1 FY 2026-27. The announcement does not state the invested-capital amount used in that calculation, and it provides neither a prior-period ROIC nor a quarterly ROIC figure.

The release does not provide volume units, product categories, geographic markets or subsidiary-level revenue and profit contributions behind the 132.30% volume increase. It also gives no standalone financial figures in the supplied highlights, despite stating that the board considered both standalone and consolidated unaudited results.

When were the results approved and what was reviewed?

Fineotex Chemical’s board meeting on November 13, 2026 began at 4.50 p.m. and concluded at 7.00 p.m. The board considered and approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

The filing was made under Regulations 30 and 33 and Schedule III of the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations, 2015. The company said limited review reports from its statutory auditors accompanied the results for the September 30, 2026 quarter and half year.

The independent auditor’s standalone review report, dated November 13, 2026, said nothing had come to its attention that caused it to believe the standalone statement was materially misstated. The report also states that a review is more limited in scope than an audit and does not provide an audit opinion.

Conclusion

Fineotex Chemical delivered substantial consolidated growth for Q2 and H1 FY 2026-27, with Q2 total income from operations rising 169.14% to Rs 391.41 crore and H1 income increasing 166.81% to Rs 778.13 crore. PAT also rose in both periods, by 70.82% to Rs 44.55 crore in Q2 and by 81.51% to Rs 92.75 crore in H1, although income growth exceeded EBITDA and PAT growth.

The next disclosures to watch are whether Fineotex Chemical provides detail on the 132.30% H1 volume increase, including product or subsidiary contributions, and explains the difference between income and earnings growth. The November 13, 2026 release also leaves the invested-capital base behind the approximately 36.12% H1 ROIC undisclosed.